Endothelium, inflammation, and diabetes.

Area of Science:

• Vascular Biology
• Endocrinology
• Cardiovascular Disease

Background:

• Normal endothelium produces vasodilators like nitric oxide (NO) and prostacyclin (PGI2) to regulate vascular tone and inflammation.
• Diabetic patients exhibit disturbed endothelial cell function, with atherosclerosis being a major cause of morbidity and mortality.
• Insulin resistance, common in obesity and type 2 diabetes, is linked to increased atherosclerosis, coronary heart disease, and stroke.

Purpose of the Study:

• To review the anti-inflammatory and potentially anti-atherogenic properties of insulin and thiazolidenediones (TZDs).
• To challenge the hypothesis that hyperinsulinemia is a common pathway for diabetic complications.
• To propose that insulin's endothelial effects confer anti-inflammatory and anti-atherogenic properties.

Main Methods:

• Literature review of studies on insulin, thiazolidenediones, endothelial function, and atherosclerosis.
• Analysis of the role of insulin in nitric oxide (NO) release and NO synthase expression.
• Examination of anti-inflammatory effects of insulin and TZDs on endothelium, leucocytes, and platelets.

Main Results:

• Insulin stimulates NO release and has vasodilator, anti-platelet, and anti-inflammatory effects, suggesting it is potentially anti-atherogenic.
• Thiazolidenediones (e.g., troglitazone, rosiglitazone) demonstrate similar anti-inflammatory effects, indicating potential anti-atherogenic roles.
• Insulin's anti-inflammatory actions may improve clinical outcomes in inflammatory conditions like acute myocardial infarction and sepsis.

Conclusions:

• Insulin possesses anti-inflammatory and potentially anti-atherogenic properties mediated through its effects on the endothelium, leucocytes, and platelets.
• TZDs share similar anti-inflammatory effects, suggesting their therapeutic potential in managing atherosclerosis in insulin-resistant states.
• These findings have significant implications for understanding atherosclerosis pathogenesis and developing comprehensive treatment strategies for insulin resistance.